Krystal Biotech diskutieren
Krystal Biotech
WKN: A2JH2F / Symbol: KRYS / Name: Krystal Biotech / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
297,50 €
6,45 %
Krystal Biotech (NASDAQ:KRYS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $240.00 price target on the stock.
Ratings data for KRYS provided by MarketBeat
Krystal Biotech (NASDAQ:KRYS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $240.00 price target on the stock.
Ratings data for KRYS provided by MarketBeat
Krystal Biotech (NASDAQ:KRYS) had its price target raised by analysts at Bank of America Corporation from $182.00 to $255.00. They now have a "buy" rating on the stock.
Ratings data for KRYS provided by MarketBeat
Der Beitrag wird untersucht
Krystal Biotech (NASDAQ:KRYS) had its price target raised by analysts at Chardan Capital from $216.00 to $220.00. They now have a "buy" rating on the stock.
Ratings data for KRYS provided by MarketBeat
Krystal Biotech (NASDAQ:KRYS) was upgraded by analysts at Citigroup Inc. from a "neutral" rating to a "buy" rating.
Ratings data for KRYS provided by MarketBeat
Krystal Biotech (NASDAQ:KRYS) had its "buy" rating reaffirmed by analysts at Cowen Inc.
Ratings data for KRYS provided by MarketBeat
Krystal Biotech (NASDAQ:KRYS) had its price target raised by analysts at TD Cowen from $202.00 to $306.00. They now have a "buy" rating on the stock.
Ratings data for KRYS provided by MarketBeat
Krystal Biotech (NASDAQ:KRYS) had its price target raised by analysts at Citigroup Inc. from $320.00 to $336.00. They now have a "buy" rating on the stock.
Ratings data for KRYS provided by MarketBeat
Krystal Biotech (NASDAQ:KRYS) had its price target raised by analysts at Bank of America Corporation from $288.00 to $318.00. They now have a "buy" rating on the stock.
Ratings data for KRYS provided by MarketBeat
Krystal Biotech (NASDAQ:KRYS) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
Ratings data for KRYS provided by MarketBeat
Krystal Biotech (NASDAQ:KRYS) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
Ratings data for KRYS provided by MarketBeat
Krystal Biotech (NASDAQ:KRYS) had its price target raised by analysts at Chardan Capital from $220.00 to $323.00. They now have a "buy" rating on the stock.
Ratings data for KRYS provided by MarketBeat
Krystal Biotech (KRYS) had its price target raised by Guggenheim from $224.00 to $284.00. They now have a "buy" rating on the stock.
Ratings data for KRYS provided by MarketBeat
Krystal Biotech (KRYS) had its "outperform" rating reaffirmed by Evercore Inc. They now have a $300.00 price target on the stock.
Ratings data for KRYS provided by MarketBeat
Krystal Biotech (KRYS) had its "buy" rating reaffirmed by HC Wainwright. They now have a $310.00 price target on the stock.
Ratings data for KRYS provided by MarketBeat
Krystal Biotech (KRYS) had its "buy" rating reaffirmed by HC Wainwright. They now have a $310.00 price target on the stock.
Ratings data for KRYS provided by MarketBeat
Krystal Biotech (KRYS) had its "buy" rating reaffirmed by HC Wainwright.
Ratings data for KRYS provided by MarketBeat
Neueste Beiträge
Barclays_PLC in Hims & Hers Health Inc. diskutieren